Antibiotic clinical trials - The Witley Park Symposium

Clinical Microbiology and Infection

Volumn 5, Issue 12, 1999, Pages 774-788

  Bax, R ^a,z   Gabbay, F ^b   Phillips, I ^c   Ball, Peter ^d   Baquero, Fernando ^e   Craig, William A ^f   Crew, Jack ^g   Dagan, Ron ^h   Garau, Javier ⁱ   Geddes, Alisdair ^j   George, Steve ^k   Gray, J A Muir ^c   Halpern, Michael ^l   Jacobs, Michael R ^m   Johnson, Tony ⁿ   Kaplan, Ed ^o   Klugman, Keith P ^p   Kristinsson, Karl G ^q   Levin, Bruce R ^r   Lockie, Cameron ^s   Mant, David ^t   Moxon, Richard ^u   Rangoonwala, Ramzan ^c   Schentag, Jerome ^v   Schlemmer, Benoît ^w   Senn, Stephen ^x   Wilson, Robert ^y   more..

^a Intl Biomed Hlthcare Sci C   (United Kingdom)

^b Rademacher Group Ltd   (United Kingdom)

^c School of Biomedical Sciences ^*

^d School of Biomedical Sciences   (United Kingdom)

^e HOSPITAL RAMÓN Y CAJAL   (Spain)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g Management Contact   (United Kingdom)

^h BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

ⁱ HOSPITAL MÚTUA DE TERRASSA   (Spain)

^j UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^k SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^l UNITED BIOSOURCE CORPORATION   (United States)

^m CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^o UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^p NATIONAL HEALTH LABORATORY SERVICE   (South Africa)

^q LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

^r EMORY UNIVERSITY   (United States)

^s Stratford Upon Avon   (United Kingdom)

^t UNIVERSITY OF OXFORD   (United Kingdom)

^u JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^v MILLARD FILLMORE HOSPITAL   (United States)

^w SAINT LOUIS HOSPITAL   (France)

^x UNIVERSITY COLLEGE LONDON   (United Kingdom)

^y NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^z Churt House   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBACTERIAL ACTIVITY; ARTICLE; CLINICAL RESEARCH; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; INFECTION; METHODOLOGY; PRIORITY JOURNAL; SYMPOSIUM;

EID: 0242294152     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00716.x     Document Type: Article

References (30)

1. Bax RP, Anderson R, Crew J, et al. Antibiotic resistance, what can we do? Nature Med 1998; 4(5): 545-6
2. Felmingham D, Gruneberg RN, The Alexander Project Group. A multicentre collaborative study of the antimicrobial susceptibility of community-acquired lower respiratory tract pathogens. J Antimicrob Chemother 1996; 38(suppl A): 1-57.
3. Bax RP. Antibiotic resistance - a view from the pharmaceutical industry. Clin Infect Dis 1997, 24(suppl): 5151-3.
4. Food and Drug Administration Modernization Act 1997.
5. Wardell WM, Lasagna L. Regulation and drug development. Washington DC American Enterprise Institute for Public Policy Research, 1975.
6. Drasdo AC, Lumley CE Efficiency in R+D. Key benchmarks. Epsom: Centre for Medicines Research, International Report CMR 95-OR, 1995.
7. Kunze ZM, Drasdo AI, Halliday RG, et al. Trends in worldwide pharmaceutical R+D. Expenditure for the 1990s. Epsom: Centre for Medicines Research, International Report CMR 95-OE, 1995.
8. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. Br Med J 1948; 2: 2769-82.
9. Thornley B, Adam C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. Br Med J 1998; 317: 1181-4.
10. Peto R, Baigent C. Trials the next 50 years. Br Med J 1998: 317; 1170-1.
11. Clarke MJ. Ovarian ablation in breast cancer 1896-1998: milestones along hierarchy of evidence from Ease reports to Cochrane Reviews. Br Med J 1998; 317: 1246-8.
12. Report of a Working Parry of the British Society for Antimicrobial Chemotherapy. The clinical evaluation of antibacterial drugs. J Antimicrob Chemother 1989; 23(suppl B).
13. Beam TR, Gilbert DN, Kunin CM. General guidelines for the clinical evaluation of anti-infective drug products. Clin Infect Dis 1992; 15(suppl 1). S5-32.
14. Beam TR, Gilbert DN, Kurun CM. General guidelines for the clinical evaluation of anti-infective drug products. Taufkirchen: European Society of Clinical Microbial and Infectious Diseases, 1993.
15. Austin DJ, Anderson RM. Studies of antibiotic resistance within the patient, hospitals and the community using simple mathematical models. Phil Trans R Soc Lond B 1999; 354: 721-38.
16. Murray C. Quantifying the burden of disease. Bull WHO 1994; 72: 429-45.
17. Nystrom PO, Bax R, Dellinger P, Knaus W, Solomkin J. Proposed definitions for diagnosis, severity scoring, stratification and outcome for trials on intra-abdominal infection. World J Surg 1990; 14: 148-58.
18. Anonymous. Pfizer Trovan suspension recommended in EU; distribution limited in US. The Pink Sheet 1999; 61(24): 11.
19. Sacket DI, Rosenberg WMC, Gray JAM, et al. Evidence based medicine: what it is and what it isn't. Br MedJ 1996; 312: 71-2.
20. Senn SJ. Falsification and clinical trials. Statistics Med 1991; 10: 1361-74.
21. Senn SJ. Inherent problems with active control equivalence studies. Statistics Med 1993; 12: 2367-75.
22. Kristinsson KG, Hjalmarsdottir MA, Gudnason T. Continued decline in the incidence of non susceptible pneumocci in Iceland [abstract 22]. In: Program and Abstracts of 38th ICAAC, San Diego. Washington DC: American Society for Microbiology, 1998: 34-5.
23. Lewis J, Facey KM. Statistical shortcomings in licencing applications. Statistics Med 1998; 17: 1663-73.
24. Ball P, Harris JM, Lowson D, et al. Acute infective exacerbations of chronic bronchitis. Q J Med 1995; 88: 61-8.
25. Marchant CD, Carlin SA, Johnson SE, et al. Measuring the comparative efficacy of antimicrobial agents for acute otitis media: the Pollyanna phenomenon. J Pacdiatr 1992; 20: 72-7.
26. Grufferman S. Complexity and the Hawthorne effect in community trials. Epidemiology 1999; 10: 209-10.
27. Bombadier C, Tugwell P. A methodological framework to develop and select indices for clinical trials. J Rheumatol 1982; 9: 753-7.
28. Remington RD. Research related to validation of treatment modalities by large scale clinical trials. Circulation 1979; 60: 1605-8.
29. Pieters T. Marketing medicine through randomised controlled trials: the case of interferon. Br Med J 1998; 317: 1231-3.
30. Hayes B, Haines A. Barriers and bridges to evidence based clinical practice. Br Med J 1998; 317: 273-6.